Quaker Houghton has closed a $550 million 7-year Term Loan B to replace existing U.S. dollar loans, extending debt maturity to 2033 and reducing annual payments. The loan, priced at SOFR +175 basis points, offers greater financial flexibility to invest in strategic growth while maintaining disciplined capital management. The company highlights strong lender support, reflecting confidence in its market position and long-term strategy. JPMorgan Chase acted as administrative agent for the deal.
Quaker Houghton's refinancing deal provides context for Industrials-sector activity on Pluang. For readers following Industrials, here is Pluang's market snapshot as of Oct 02, 2026 02:51 WIB: Among 93 priced US Industrials stocks, 69 rose and 24 fell. Notable movers include SBLK at USD 30.54 with a 4.02% increase and 100% buy order activity, CHRW at USD 153.80 up 3.95% with 100% buy orders, and ENVX at USD 2.79 down 3.62% with 89% buy orders and 11% sell orders.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
